Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleClinical StudiesR

Ras Mutational Status Is a Biomarker for Resistance to EGFR Inhibitors in Colorectal Carcinoma

WOLFRAM C.M. DEMPKE and VOLKER HEINEMANN
Anticancer Research November 2010, 30 (11) 4673-4677;
WOLFRAM C.M. DEMPKE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wolfram.dempke{at}elblandkliniken.de
VOLKER HEINEMANN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 30 no. 11 4673-4677
PMID 
21115922

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received July 16, 2010
  • Revision received October 13, 2010
  • Accepted October 18, 2010
  • Published online November 29, 2010.

Copyright & Usage 
Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. WOLFRAM C.M. DEMPKE1 and
  2. VOLKER HEINEMANN2
  1. 1Elbland Clinic Riesa, Medical Oncology, D-01589 Riesa, Germany
  2. 2University of Munich, University Hospital of Grosshadern (Hematology and Oncology), D-81377 Munich, Germany
  1. Correspondence to: Wolfram C.M. Dempke, MD, Ph.D., Elbland Clinic Riesa, Medical Oncology, Weinbergstrasse 8, D-01589 Riesa, Germany. Tel: +49 3525753552, Fax: +49 3525753578, e-mail: wolfram.dempke{at}elblandkliniken.de
View Full Text

Statistics from Altmetric.com

Cited By...

  • 35 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 30, Issue 11
November 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Ras Mutational Status Is a Biomarker for Resistance to EGFR Inhibitors in Colorectal Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Ras Mutational Status Is a Biomarker for Resistance to EGFR Inhibitors in Colorectal Carcinoma
WOLFRAM C.M. DEMPKE, VOLKER HEINEMANN
Anticancer Research Nov 2010, 30 (11) 4673-4677;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Ras Mutational Status Is a Biomarker for Resistance to EGFR Inhibitors in Colorectal Carcinoma
WOLFRAM C.M. DEMPKE, VOLKER HEINEMANN
Anticancer Research Nov 2010, 30 (11) 4673-4677;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • EGFR and Ras Oncogenes: Molecular Biology
    • Clinical Data
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Cancer cell states and emergent properties of the dynamic tumor system
  • Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer
  • GA201 (RG7160): A Novel, Humanized, Glycoengineered Anti-EGFR Antibody with Enhanced ADCC and Superior In Vivo Efficacy Compared with Cetuximab
  • Google Scholar

More in this TOC Section

  • The Prognostic Impact of Perioperative Inflammatory Status in Elderly Patients With Gastric Cancer
  • Preoperative Serum Total Cholesterol Predicts Adjuvant Chemotherapy Completion After Pancreaticoduodenectomy for Pancreatic Cancer
  • Predictive Role of PSA Kinetics in Oncological Outcomes of Metastatic Castration-sensitive Prostate Cancer
Show more Clinical Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire